3 Mid-Cap Stocks We Find Risky

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

This is precisely where StockStory comes in - we do the heavy lifting to identify companies with solid fundamentals so you can invest with confidence. Keeping that in mind, here are three mid-cap stocks to avoid and some other investments you should consider instead.

Veralto (VLTO)

Market Cap: $24.51 billion

Spun off from Danaher in 2023, Veralto (NYSE:VLTO) provides water analytics and treatment solutions.

Why Are We Wary of VLTO?

1. Annual revenue growth of 4.4% over the last four years was below our standards for the industrials sector
2. Demand will likely be soft over the next 12 months as Wall Street’s estimates imply tepid growth of 5.4%

Veralto is trading at $98.70 per share, or 24.1x forward P/E. If you’re considering VLTO for your portfolio, see our FREE research report to learn more.

Biogen (BIIB)

Market Cap: $25.54 billion

Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ:BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases.

Why Is BIIB Not Exciting?

1. Annual sales declines of 6.7% for the past five years show its products and services struggled to connect with the market during this cycle
2. Projected sales decline of 9.8% for the next 12 months points to an even tougher demand environment ahead
3. Earnings per share have contracted by 13.2% annually over the last five years, a headwind for returns as stock prices often echo long-term EPS performance

Biogen’s stock price of $174.19 implies a valuation ratio of 13.4x forward P/E. To fully understand why you should be careful with BIIB, check out our full research report (it’s free for active Edge members).

Flex (FLEX)

Market Cap: $25.44 billion

Originally known as Flextronics until its 2016 rebranding, Flex (NASDAQ:FLEX) is a global manufacturing partner that designs, engineers, and builds products for companies across industries from medical devices to solar trackers.

Why Do We Think Twice About FLEX?

1. Sales tumbled by 3.1% annually over the last two years, showing market trends are working against its favor during this cycle
2. Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
3. Diminishing returns on capital suggest its earlier profit pools are drying up

At $69.20 per share, Flex trades at 21.5x forward P/E. Dive into our free research report to see why there are better opportunities than FLEX.

Stocks We Like More

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.